

**BioNovelus, Inc.**  
**Balance Sheets**  
**As of March 31, 2016 and December 31, 2015**

	<b>March 31, 2016</b>	<b>December 31, 2015</b>
	<u>                    </u>	<u>                    </u>
<b>ASSETS</b>		
<b>Current Assets</b>		
Checking/Savings		
Cash	4	134
<b>Total Checking/Savings</b>	<u>4</u>	<u>134</u>
Account Receivable	0	0
<b>Total Current Assets</b>	<u>4</u>	<u>134</u>
<b>Fixed Assets</b>		
Accumulated Amortization	(46,708)	(35,031)
Intellectual Property	700,620	700,620
<b>Total Fixed Assets</b>	<u>653,912</u>	<u>665,589</u>
<b>TOTAL ASSETS</b>	<u><b>653,916</b></u>	<u><b>665,723</b></u>
<b>LIABILITIES &amp; EQUITY</b>		
<b>Liabilities</b>		
<b>Current Liabilities</b>		
Accounts Payable		
Accounts Payable Ekobo	9,795	9,300
<b>Total Accounts Payable</b>	<u>9,795</u>	<u>9,300</u>
<b>Other Current Liabilities</b>		
Accrued Interest	37,386	29,868
Accrued Interest - Officers	9,397	7,582
Loan from Ekobo	330	330
Loan from Ben & Karen Kim	0	0
Loan from James Termine	73,676	73,676
<b>Total Other Current Liabilities</b>	<u>120,789</u>	<u>111,456</u>
Notes Payable to Officers	244,576	240,816
Notes Payable to Related Parties	100,000	100,000
<b>Notes Payable Unrelated Parties</b>		
Note Payable - James P Perrine	1,000	1,000
Note Payable #1 -	2,500	2,500
Note Payable #10 -	25,000	25,000
Note Payable #11 -	12,500	12,500
Note Payable #14 -	50,000	50,000
Note Payable #2 -	15,060	15,060
Note Payable #3 -	7,000	7,000
Note Payable #4 -	25,500	25,500
Note Payable #5 -	5,785	5,785
Note Payable #6 -	10,000	10,000
Note Payable #7 -	25,000	25,000
Note Payable #8 -	1,500	1,500
Note Payable #9 -	25,000	25,000
<b>Total Notes Payable Unrelated Parties</b>	<u>205,845</u>	<u>205,845</u>
<b>Total Current Liabilities</b>	<u>681,005</u>	<u>667,417</u>
<b>Total Liabilities</b>	681,005	667,417
<b>Equity</b>		
Common Stock	83,268	83,268
Paid in Capital	666,381	666,381
Preferred Stock	10,000	10,000
Retained Earnings	(761,343)	(638,684)
Net Income	(25,395)	(122,658)
<b>Total Equity</b>	<u>(27,089)</u>	<u>(1,694)</u>
<b>TOTAL LIABILITIES &amp; EQUITY</b>	<u><b>653,916</b></u>	<u><b>665,723</b></u>

**BioNovelus, Inc.**  
**Footnotes to Financial Statements**  
**For the Quarter Ending March 31, 2016**

NOTE 1 -ORGANIZATION

BioNovelus Inc. (BioNovelus) is an Arizona based biotech company that aims to develop a portfolio of green solutions for many applications. The solutions address major global challenges: food and water safety and supply.

BioNovelus was founded in September 2010 to answer critical environmental problems by replacing harmful chemicals with eco-friendly and profitable technology to aid our planet.

NOTE 2 -SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation: Information and note disclosures in these financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").

Cash and Cash Equivalents: Cash and cash equivalents consists of cash on hand, undeposited funds, amounts on deposit with financial institutions and certificates of deposit available for withdrawal.

Intellectual Property - All research and development costs are normally expensed as incurred. Since there was a reverse acquisition/merger in May 2015 with Firstin Wireless Technology, Inc. , those rules change per GAAP. Stock is being issued for the product, the cost of the stock (which is \$0.01 per share) becomes the fair market value based on the number of shares. To calculate the fair market value, the number of shares was multiplied by \$0.01 to come up with the fair market value.

Income Taxes: The company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing tax assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled.

Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

### NOTE 3 - Concentration of Risk

BioNovelus maintains cash and cash equivalents at various financial institutions. Deposits not to exceed \$250,000 at each financial institution are insured by the Federal Deposit Insurance Corporation. As of March 31, 2016, BioNovelus's bank balances did not exceed this limit.

### NOTE 4 - Related Parties Debt

BioNovelus has outstanding notes payable to its President for \$244,576 and others for \$100,000 as of March 31, 2016. There are several unsecured notes but the terms are consistent as follows:

Due on demand with 3% interest

In addition, there are loans payable of \$74,006 to officers and other related parties. These loans are not secured and do not accrue interest. Principal is due on demand.

### NOTE 5 - Notes Payable

BioNovelus has outstanding notes payable of \$205,845 as of March 31, 2016. The terms of the notes are as follows:

Unsecured demand notes at 3% interest per annum	\$51,000
Convertible notes 1t 11% interest with various due dates in 2016	\$154,845

**BioNovelus, Inc.**  
**Income Statements**  
**For the Period Ending March 31, 2016**  
**and December 31, 2015**

	<b>Three Months Ending</b>	<b>Year Ending</b>
	<b>March 31, 2016</b>	<b>December 31, 2015</b>
Ordinary Income/Expense		
Expense		
Accounting	-	2,500
Advertising and Promotion	274	1,053
Amortization Expense	11,676	35,031
Auto and Truck Expenses	16	498
Bank Service Charges	140	221
Car rental	-	463
Cleaning	-	33
Computer and Internet Expenses	12	359
Interest Expense	9,333	37,450
Lab Testing	-	4,250
Licenses & Permits	-	895
Mail Service	115	451
Meals and Entertainment	404	1,262
N/P Ekobo	-	1,025
Office Supplies	23	490
Parking	-	12
Printing and Reproduction	58	10
Professional Fees		
Grant Fees	-	750
Legal Fees	-	275
Professional Fees - Other	-	16,651
Total Professional Fees	<u>-</u>	<u>17,676</u>
Research & Development	-	1,500
SCC & OTC Filing	300	12,683
Stock Management	-	1,545
Subscription	-	30
Taxes	-	64
Telephones	1,056	-
Travel	1,988	2,392
Travel Expense	-	767
Total Expense	<u>25,395</u>	<u>122,658</u>
Net Ordinary Income	<u>(25,395)</u>	<u>(122,658)</u>
Net Income	<u><u>(25,395)</u></u>	<u><u>(122,658)</u></u>

**BioNovelus, Inc.**  
**Statements of Cash Flows**  
**For the Period Ending March 31, 2016**  
**and December 31, 2015**

	<b>Three Months Ending</b>	<b>Year Ending</b>
	<b>March 31, 2016</b>	<b>December 31, 2015</b>
<b>OPERATING ACTIVITIES</b>		
Net Income	-25,395	-122,658
Adjustments to reconcile Net Income to net cash provided by operations:		
Accounts Payable Ekobo	495	9,300
Accrued Interest	7,518	29,868
Accrued Interest - Officers	1,815	7,582
Loan from Ekobo	0	330
Loan Repayment from Ben & Karen Kim	0	16,250
Loan from James Termine	0	38,701
Account Receivable	0	0
<b>Net cash provided by Operating Activities</b>	<b>-15,567</b>	<b>-20,627</b>
<b>INVESTING ACTIVITIES</b>		
Accumulated Amortization Intellectual Property	11,677	35,031
	0	-700,620
<b>Net cash provided by Investing Activities</b>	<b>11,677</b>	<b>-665,589</b>
<b>FINANCING ACTIVITIES</b>		
Notes Payable to Officers:Note Payable #13 -J Ekobo	0	130,000
Notes Payable to Officers:Note Payable #15 - JN Ekobo	0	7,500
Notes Payable to Officers:Note Payable #16 - JN Ekobo	0	7,500
Notes Payable to Officers:Note Payable #17 - JN Ekobo	0	4,700
Notes Payable to Officers:Note Payable #18 - JN Ekobo	0	55,731
Notes Payable to Officers:Note Payable #19 - JN Ekobo	0	4,500
Notes Payable to Officers:Note Payable #20 - JN Ekobo	0	5,030
Notes Payable to Officers:Note Payable #21 - JN Ekobo	0	16,055
Notes Payable to Officers:Note Payable #22 - JN Ekobo	0	5,500
Notes Payable to Officers:Note Payable #24 - JN Ekobo	0	3,000
Notes Payable to Officers:Note Payable #25 - Jean Ekob	0	900
Notes Payable to Officers:Note Payable #26 - Jean Ekob	0	400
Notes Payable to Officers:Note Payable #27 - Jean Ekob	3,760	0
Notes Payable toRelated Parties:Note Payable #12 - Teri	0	100,000
Notes Payable Unrelated Parties:Note Payable - James I	0	1,000
Notes Payable Unrelated Parties:Note Payable #1 -	0	2,500
Notes Payable Unrelated Parties:Note Payable #10 -	0	25,000
Notes Payable Unrelated Parties:Note Payable #11 -	0	12,500
Notes Payable Unrelated Parties:Note Payable #14 -	0	50,000
Notes Payable Unrelated Parties:Note Payable #2 -	0	15,060
Notes Payable Unrelated Parties:Note Payable #3 -	0	7,000
Notes Payable Unrelated Parties:Note Payable #4 -	0	25,500
Notes Payable Unrelated Parties:Note Payable #5 -	0	5,785
Notes Payable Unrelated Parties:Note Payable #6 -	0	10,000
Notes Payable Unrelated Parties:Note Payable #7 -	0	25,000
Notes Payable Unrelated Parties:Note Payable #8 -	0	1,500
Notes Payable Unrelated Parties:Note Payable #9 -	0	25,000
Common Stock	0	83,268
Equity from Charles Kim	0	-8,560
Equity from Ekobo	0	-10,798
Paid in Capital	0	666,381
Preferred Stock	0	10,000
Retained Earnings	0	-605,707
<b>Net cash provided by Financing Activities</b>	<b>3,760</b>	<b>681,245</b>
<b>Net cash increase for period</b>	<b>-130</b>	<b>-4,971</b>
Cash at beginning of period	134	5,106
<b>Cash at end of period</b>	<b>4</b>	<b>134</b>

**BioNovelus, Inc.**  
**Statement of Stockholders Equity**  
**For the Period Ending March 31, 2016**  
**and December 31, 2015**

	Preferred Stock		Common Stock		Additional Paid in Capital	Retained Earnings Accumulated deficit	Total
	# of Shares	Amount	# of Shares	Amount			
Balance, December 31, 2014	-	-	-	-	19,358	(638,684)	(619,326)
Return to Treasury		-	-	-	(19,358)	-	(19,358)
New Shares	10,000,000	10,000		-	-	-	10,000
Issued From Treasury - Acquisition			70,062,003	70,062	630,558	-	700,620
Sale of Stocks			5,386	5	-	-	5
Note Payables Converted to Stocks			13,200,580	13,201	27,225	-	40,426
Loan Paid in Conjunction with Paid in Capital				-	8,598	-	8,598
Net Loss Fiscal Year December 31, 2015				-	-	(122,658)	(122,658)
<b>Balance, December 31, 2015</b>	<b>10,000,000</b>	<b>10,000</b>	<b>83,267,969</b>	<b>83,268</b>	<b>666,381</b>	<b>(761,343)</b>	<b>(1,694)</b>
Net Loss for the three months ended March 31, 2016						(25,395)	(25,395)
<b>Balance, March 31, 2016</b>	<b>10,000,000</b>	<b>10,000</b>	<b>83,267,969</b>	<b>83,268</b>	<b>666,381</b>	<b>(786,738)</b>	<b>(27,089)</b>

-----